New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
07:06 EDTTBIOTransgenomic enters agreement with DNA Technologies
Transgenomic announced that it has entered into an agreement to sell to Integrated DNA Technologies the rights to Transgenomic’s SURVEYOR Nuclease technology and assets for a minimum of $4.25M. Under the terms of the agreement, IDT will make an upfront payment of $3.65M and additional minimum payments of $0.6M or more to Transgenomic during the first year of the agreement. Transgenomic will transfer rights to the SURVEYOR patents, license, technology, know-how and trademarks to IDT, as well as all inventory of the product. As part of the agreement, IDT will exclusively sublicense rights for all clinical and diagnostic applications of the SURVEYOR technology back to Transgenomic. Further terms of the agreement were not disclosed.
News For TBIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2016
07:34 EDTTBIOTransgenomic says Multiplexed ICE COLD-PCR enables personalized medicine R&D
Transgenomic announced that Ben Legendre, Jr., PhD, Vice President, Laboratory Operations, delivered a presentation yesterday at the Personalized Medicine World Conference. In his talk, Legendre highlighted how Transgenomic's Multiplexed ICE COLD-PCR technology enables personalized medicine R&D, exemplified by its utility for stratification of clinical study patients in partnership with Transgenomic's pharmaceutical and biotechnology clients. In addition, the accuracy of MX-ICP and its ability to enable use of liquid biopsies are supporting the rapidly growing use of personalized and precision medicine strategies in routine clinical practice. In his talk, Legendre described how MX-ICP delivers enrichment of gene regions that allows determination of all point mutations and insertions/deletions. He noted that the ability of MX-ICP to efficiently detect genetic alterations down to 0.01% in blood and tissue samples and to increase the sensitivity of almost all downstream analysis platforms serve to make efficient detection of mutations feasible and practical for most laboratories. And the multiplexed format of MX-ICP allows sensitive detection and monitoring of all genetic alterations in multiple targets using a single DNA sample.
January 25, 2016
17:12 EDTTBIOTransgenomic files to sell 1.11M shares of common stock for holders
Subscribe for More Information
16:54 EDTTBIOTransgenomic files to sell 7.12M shares of common stock for holders
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use